This can be a short description about this vertical and all the great links contained therein.
R&D Strategy
Evidence
Pipeline
Clinical Trials
Article originally published February 2026 […]
Learn More ›
This can be a short description about this vertical and all the great links contained therein.
First-ever FDA authorized AI sepsis diagnostic tool with powerful diagnostic and predictive capabilities
5th World Sepsis Congress | […]
Learn More ›
This can be a short description about this vertical and all the great links contained therein.
Resource Library
Events
Sepsis ImmunoScore® demonstrates stronger predictive […]
Learn More ›
Read the latest Prenosis peer-reviewed articles and items from scholarly journals.
Newsroom
Sepsis ImmunoScore® demonstrates stronger predictive […]
Learn More ›
Read the latest Prenosis peer-reviewed articles and items from scholarly journals.
Mission, Vision, Values
Careers
Leadership
Awards
AI in Chicago | Episode […]
Learn More ›
Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. NORTH BRUNSWICK, N.J., April 21, 2026 (GLOBE...
Release originally posted on Crain’s Chicago Business Chicago-based sepsis diagnosing biotech Prenosis announced two $20 million milestones this morning, Series A financing and a large government contract. Read full release >
Release originally posted on hlth.com Prenosis has announced the completion of a $20M Series A financing round alongside a $20M federal contract from the Biomedical Advanced Research and Development Authority (BARDA), bringing total new funding to $40M. The...
Release originally posted on Chicago Business Journal A local medtech startup behind an AI sepsis diagnostic tool recognized by TIME magazine has landed $40 million in funding. Read full release >
Release originally posted on HIT Consultant The Chicago-based health tech company Prenosis revealed a dual milestone: the closing of a $20M Series A financing round and the awarding of a $20M contract from the Biomedical Advanced Research and Development Authority...
Latest fundraising efforts accelerate further innovation in biology-based diagnostics and therapeutics for critical care conditions CHICAGO, IL – January 29, 2026 – Prenosis, a biology-based technology company delivering integrated diagnostics and therapeutics,...
Company’s AI-powered diagnostic is shaping the future of sepsis care CHICAGO, IL – November 14, 2025 – Prenosis has been named a winner of the 24th Annual Chicago Innovation Awards, the region’s foremost recognition of the most innovative new products and services...
Finalist recognition validates Prenosis’ pioneering work in AI-driven diagnostics for sepsis and its impact on critical care decision-making Chicago, IL – October 8, 2025 — Prenosis has been named a Finalist in the 2025 Digital Health Hub Foundation: Digital Health...
Prenosis’ Sepsis ImmunoScore™, Innovative Sepsis Diagnostic Technology, Now Supported by Enhanced Documentation and Reimbursement Pathway CHICAGO, IL – October 1, 2025 – The Centers for Medicare & Medicaid Services (CMS) has officially released the FY 2026...
Chicago-based Prenosis recognized for pushing the boundaries of biology and AI in acute care innovation CHICAGO, IL – September 24, 2025 – Prenosis has been named one of the Top 100 Finalists for the 24th Annual Chicago Innovation Awards, which celebrates the most...